Two Track Biologic Therapy for Concurrent Chronic Spontaneous Urticaria and Psoriasis Vulgaris in One Patient

Benko, Maja; Stančič, Bor Hrvatin; Lunder, Tomaz

doi:10.1016/j.ad.2021.02.029

Cited by 3 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common reason for using second biological agents was usually psoriasis like our study. In a case report, it was reported that a male patient received guselkumab for psoriasis and omalizumab for CSU for a period of 21 months without any clinically relevant adverse effect and drug interactions 10 . As in most of the patients in our study, omalizumab was also started during guselkumab treatment.…”

Section: Discussionmentioning

confidence: 67%

“…8 There are few case reports in the literature reporting the use of different biological agents simultaneously used with omalizumab. [9][10][11] For this reason, this study was aimed to retrospectively evaluate the patients with CSU using omalizumab who received concurrent different biological agents due to any other dermatological diagnosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Omalizumab treatment in combination with any other biologics: Is it really a safe duo?

Yıldırım

Erbağcı

Hapa³

2023

Aust J Dermatology

View full text Add to dashboard Cite

Background: Chronic spontaneous urticaria (CSU) is a mast cell-mediated disease, which is sometimes associated with various inflammatory disorders.Omalizumab is a commonly used biological agent, which is a recombinant, humanized, monoclonal antibody against human immunoglobulin E. However, there are only few reports about the combination of omalizumab for CSU with any other biologics for accompanying inflammatory diseases in the literature. The aim of this study was to evaluate the patients whose treatment of omalizumab for CSU were combined with any other biologics for associated inflammatory disorders and to describe whether these combinations might have any safety concerns. Methods:We conducted a retrospective cohort study of adult patients with CSU treated with omalizumab concurrently using another biological agent for their other dermatological conditions.Results: Thirty-one patients, 19 women and 12 men, were evaluated. The mean age was 45.13 years. The median duration of omalizumab was 11 months.Biological agents which patients were treated other than omalizumab were as follows: adalimumab biosimilar (n = 3), ustekinumab (n = 4), secukinumab (n = 17) and ixekizumab (n = 7). The median duration of concurrent use of omalizumab and other biologics was 8 months. None of the drug combinations was stopped because of side effects. Conclusion:This observational study demonstrated that omalizumab treatment for CSU in combination with any other biological agents for dermatological disorders appeared to be well tolerated without any major safety concerns.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Omalizumab treatment in combination with any other biologics: Is it really a safe duo?

Yıldırım

Erbağcı

Hapa³

2023

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…Concomitant use of guselkumab and OMZ for psoriasis and CSU showed no clinically significant side effects during an extended treatment course of 21 months. 6 OMZ combined with biologics may achieve a better outcome in psoriasis than biologics. [6][7][8] Since all published articles were limited to case reports, the relation between psoriasis and urticaria remains uncertain (Table 1).…”

Section: Response Of Chronic Refractory Psoriasis Vulgaris With Urtic...mentioning

confidence: 99%

“…6 OMZ combined with biologics may achieve a better outcome in psoriasis than biologics. [6][7][8] Since all published articles were limited to case reports, the relation between psoriasis and urticaria remains uncertain (Table 1). Based on a single case of psoriasis remission on CSU exacerbation, Magen and Chikovani thought CSU would be found at a lower frequency in patients with psoriasis and vice versa, if more evidence exist.…”

Section: Response Of Chronic Refractory Psoriasis Vulgaris With Urtic...mentioning

confidence: 99%

See 1 more Smart Citation

Response of chronic refractory psoriasis vulgaris with urticaria to combined secukinumab and omalizumab: A case report and review of the literature

Abdelmaksoud

Temiz

Daye

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Multiple drugs

2024

Reactions Weekly

View full text Add to dashboard Cite

Two Track Biologic Therapy for Concurrent Chronic Spontaneous Urticaria and Psoriasis Vulgaris in One Patient

Cited by 3 publications

References 2 publications

Omalizumab treatment in combination with any other biologics: Is it really a safe duo?

Omalizumab treatment in combination with any other biologics: Is it really a safe duo?

Response of chronic refractory psoriasis vulgaris with urticaria to combined secukinumab and omalizumab: A case report and review of the literature

Multiple drugs

Contact Info

Product

Resources

About